knowledge -WSS

knowledge

author：entertainment 2025-09-30 22:05:53 - browse：8368

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Novo acquires Inversago for up to $1 billion

WSS

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Novo acquires Inversago for up to $1 billion

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

TB outbreak tied to bone grafts underscores testing shortcomings

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Moonlake's readout produced a cash windfall. Risks remain

The history of OxyContin, told through Purdue Pharma documents

Drug repurposing or repositioning? The language matters

How dance can help nurses traumatized by Covid

Apple is now the first public company to be valued at $3 trillion

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Virginia high school admissions case could be legal follow

Medicare to cover more brain scans for Alzheimer’s patients

Apple is now the first public company to be valued at $3 trillion

Google and Epic fight stronger regulation of AI in health care

Wikipedia

Listen: Wegovy in the brain & pivotal Alzheimer's data

A public scorecard can help hold safety

How dance can help nurses traumatized by Covid

STAT Virtual Event: The State of Biosimilars: What to Watch

Sanofi seeks simpler, safer CRISPR sickle cell cure

Why hospitals are withdrawing from US News rankings

focus

hotspot

focus

entertainment